Psych MEQs / SAQs · Old age psychiatry — residential care and systems of care
Residential aged care psychiatry — behavioural crisis and prescribing (MEQ)
FRANZCP-style MEQ on RAC psychiatry: multifactorial assessment, person-centred care, pain protocol, antipsychotic mortality evidence, deprescribing, chemical restraint, capacity.
On this page & tools
Target exams
Model answer
Reveal model answer
(i) Assessment. Behavioural change in RAC is multifactorial. Structure: safety (aggression, falls, absconding); collateral from staff and family for time course and baseline; medical screen for delirium, infection, pain, constipation, retention, dehydration, hypoxia; medication review (oxybutynin anticholinergic burden; temazepam sedative/deliriogenic); define target behaviours with ABC charting and NPI-style domains; risk and capacity/proxy map. High psychiatric morbidity in LTC means do not dismiss symptoms, but do not label every crisis as primary psychosis.[1][2]
(ii) Non-drug care. First-line is person-centred care, meaningful activity, sensory aids, consistent approach to personal care, and staff training. Fossey cluster RCT: enhanced psychosocial care reduced antipsychotic use in severe dementia nursing homes without significantly worsening behaviour. WHELD/person-centred packages improve quality of life and agitation metrics and can reduce antipsychotic use. Husebo: protocolised pain treatment reduces behavioural disturbance in nursing-home dementia — treat pain before escalating psychotropics. Stop or minimise oxybutynin and temazepam if safer alternatives exist.[4][5][6]
(iii) Antipsychotics. Benefits are modest and symptom-targeted for severe distress or danger only. Harms: Schneider meta-analysis — increased death with atypical antipsychotics in dementia RCTs; observational mortality and serious-event data (Gill/Huybrechts/Rochon class of evidence). If continued briefly for clear risk: lowest dose (e.g. risperidone 0.25–0.5 mg range), ECG/falls monitoring, documented target, consent/proxy, review/stop date. DART-AD: continuing neuroleptics is not clearly advantageous for many; long-term follow-up raised mortality concerns with continued treatment — plan deprescribing when stable.[3][7][8]
(iv) Restraint, capacity, disposition. Near-daily PRN without documented indication risks chemical restraint framing — document therapeutic purpose or stop. Capacity is decision-specific for psychotropic consent and transfer; engage proxy under local law. Disposition: optimise in place with old-age liaison/DBMAS-style support; hospital only if medical instability or risk exceeds facility capacity. Reassurance to staff that evidence-based non-drug care can reduce drug reliance is part of systems leadership.[2][4]
References
- [1]Seitz D, Purandare N, Conn D Prevalence of psychiatric disorders among older adults in long-term care homes: a systematic review Int Psychogeriatr, 2010.PMID 20522279
- [2]Kales HC, Gitlin LN, Lyketsos CG Assessment and management of behavioral and psychological symptoms of dementia BMJ, 2015.PMID 25731881
- [3]Schneider LS, Dagerman KS, Insel P Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials JAMA, 2005.PMID 16234500
- [4]Fossey J, Ballard C, Juszczak E, et al. Effect of enhanced psychosocial care on antipsychotic use in nursing home residents with severe dementia: cluster randomised trial BMJ, 2006.PMID 16543297
- [5]Ballard C, Corbett A, Orrell M, et al. Impact of person-centred care training and person-centred activities on quality of life, agitation, and antipsychotic use in people with dementia living in nursing homes: A cluster-randomised controlled trial PLoS Med, 2018.PMID 29408901
- [6]Husebo BS, Ballard C, Sandvik R, et al. Efficacy of treating pain to reduce behavioural disturbances in residents of nursing homes with dementia: cluster randomised clinical trial BMJ, 2011.PMID 21765198
- [7]Ballard C, Lana MM, Theodoulou M, et al. A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (the DART-AD trial) PLoS Med, 2008.PMID 18384230
- [8]Ballard C, Hanney ML, Theodoulou M, et al. The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial Lancet Neurol, 2009.PMID 19138567